The initial success of the copyright undeniably reshaped the medication landscape, but investing in companies heavily reliant on off-patent versions presents a uncertain picture. Despite early profits were substantial, the cessation of patents and the rise of discounted alternatives have eroded market share. Thus, a thorough assessment of current i